

# Exports

[cphi.evapharma.com](http://cphi.evapharma.com)

2021



EVA PHARMA







# About Us

At EVA Pharma, we pride ourselves on our innovation and our expertise, built on a heritage spanning over a hundred years.

We have a presence in more than 40 countries worldwide, with a particularly strong footprint in the Middle East and Africa, where we have sales teams on the ground in many countries. Our current export markets include the Middle East and Africa, Southeast Asia, and Central America.





# Building Successful Partner- ships

EVA Pharma has a record of successful partnerships in a variety of areas.

We have been recognized as the partner of choice by several multinational companies in Europe through out-licensing the company's unique eCTD dossiers, which are now registered in more than ten EU countries.

In 2019, we partnered with Gilead Sciences to become a licensed distributor for their HIV, HBV and HCV products in Africa, and in 2020 we acquired the license to manufacture and distribute Gilead's COVID-19 antiviral remdesivir, going on to export it to dozens of countries.

In addition, in 2020, EVA Group signed a strategic partnership agreement with Eli Lilly and Company to import, distribute, market and sell Lilly's portfolio of brands in Egypt.








# Partner With Us

For export partnerships, we offer an EMA-approved facility with complete CTD dossiers with BEs.

We have dedicated production facilities for immunosuppressants and cephalosporins, a sterile production area, and the capacity to produce a variety of dosage forms (including oral solids, liquids, semisolids, sachets, Soft gelatin, DBI, and Mono-dose eye drops).

## Our portfolio includes:

- Limitless Naturals food
- supplements
- eye drops
- immunosuppressants
- Antiviral
- diabetes
- COVID-19 vaccine (under-development)



**EVA PHARMA**  
SECURING YOUR HEALTH

**To find out more about partnering  
with EVA Pharma, contact us on:**

[cphi.evapharma.com](http://cphi.evapharma.com)